Neurogene (NGNE) Total Liabilities (2013 - 2026)

Neurogene has reported Total Liabilities for 14 years, with the latest figure at $25.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 7.88% year-over-year to $25.4 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (up 7.88% YoY), and the FY2025 full-year result was $23.7 million, down 6.46% from the prior year.
• Total Liabilities for Q1 2026 stood at $25.4 million, up from $23.7 million in the prior quarter.
• The five-year high for Total Liabilities was $36.5 million in Q4 2023, with the low at $10.6 million in Q4 2022.
• Historically, Total Liabilities has averaged $22.0 million across 5 years, with a median of $23.5 million in 2025.
• Annual changes were most pronounced in 2022 — Total Liabilities sank 47.85% — and 2023, when it surged 243.57%.
• Neurogene's Total Liabilities stood at $10.6 million in 2022, then surged by 243.57% to $36.5 million in 2023, then tumbled by 30.63% to $25.4 million in 2024, then retreated by 6.46% to $23.7 million in 2025, then rose by 6.92% to $25.4 million in 2026.
• The last three Total Liabilities figures came in at $25.4 million (Q1 2026), $23.7 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.